T
Tamurobio
This biotechnology company is developing a pre-clinical therapeutic candidate that sequesters lipotoxic products to treat non-alcoholic steatohepatitis (NASH) and Type 2 diabetes. By targeting these conditions, the company aims to prevent chronic liver disease and improve patient health outcomes.
Traction –/10
McLean, United States · HQ
- Biotechnology
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This biotechnology company is developing a pre-clinical therapeutic candidate that sequesters lipotoxic products to treat non-alcoholic steatohepatitis (NASH) and Type 2 diabetes. By targeting these conditions, the company aims to prevent chronic liver disease and improve patient health outcomes.